There are no simple answers to questions such as ‘Which antidepressant is most likely to cause seizures?’ or ‘Which antipsychotic drug is the safest to use in a patient with a seizure disorder?’
The risk of psychotropic drug-induced seizures is dependent on many factors beyond inherent differences in the propensity of individual drugs to lower seizure threshold. Individual patient variables that affect the likelihood of drug-induced seizures occurring include a history of epilepsy or seizures, a family history of epilepsy, and postnatal brain damage, head trauma and dementia. Once a drug is selected, seizure risk is directly dependent on dosage, rate and amount of dose titration, and concurrent use of other drugs.
Setting aside these other risk factors, the likelihood of drug-induced seizures occurring does differ among psychotropic drugs. Among antipsychotic drugs, clozapine is associated with the highest risk of seizures, followed by chlorpromazine, with other phenothiazines and risperidone having a lower risk and haloperidol the least risk.
Among antidepressants, maprotiline, amoxapine, amfebutamone (bupropion) and clomipramine pose the greatest risk along with other tricyclic antidepressants in high doses. Monoamine oxidase inhibitors (MAOIs), trazodone, nefazodone and the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) are associated with a lower risk of seizures.
Benzodiazepines with long elimination half-lives are less likely to cause seizures during withdrawal than those agents with short to intermediate half-lives, although the rate and amount of dosage reduction are more important variables.
Finally, most psychotropic drugs are metabolised by cytochrome P450 isoenzymes. Concurrent use of enzyme inhibitors or discontinuation of enzyme inducers may cause a significant increase in plasma concentrations of the psychotropic drug, increasing the likelihood of adverse effects and the potential for seizures.
Small JG, Milstein V, Small IF, et al. Computerized EEG profiles of haloperidol, chlorpromazine, c1ozapine, and placebo in treatment resistant schizophrenia. Clin Electroencephalogr 1987; 18: 124–35PubMedGoogle Scholar
Trimble M. The relationship between epilepsy and schizophrenia: a biochemical hypothesis. Biol Psychiatry 1977; 12: 299–304PubMedGoogle Scholar
Olson KR, Kearney TE, Dyer JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1993; 11: 565–8PubMedCrossRefGoogle Scholar
Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967; 17: 869–77Google Scholar
Hil TM, Soldatos C. Epileptogenic side effects of psychotropic drugs. JAMA 1980; 244: 1460–3CrossRefGoogle Scholar
Funderburg LG, Vertrees JE, True JE, et al. Seizure following addition of erythromycin to c10zapine treatment [letter]. Am J Psychiatry 1994; 151: 1840–1PubMedGoogle Scholar
Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of c10zapine and its major metabolites: effects of cotreatrnent with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123–5PubMedGoogle Scholar
Wilson WH, Claussen AM. Seizures associated with c10zapine treatment in a state hospital. J Clin Psychiatry 1994; 55: 184–8PubMedGoogle Scholar
Devinsky O, Pacia SV. Seizures during c10zapine therapy. J Clin Psychiatry 1994; 55 (9) Suppl.B: 153–6PubMedGoogle Scholar
Kando JC, Tohen M, Castillo J, et al. Concurrent use of c1ozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994; 55: 255–7PubMedGoogle Scholar
Ojemann LM, Friel PN, Trejo WJ, et al. Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology 1983; 33: 646–8PubMedCrossRefGoogle Scholar
Wroblewski BA, McColgan K, Smith K, et al. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. J Clin Psychopharmacol 1990; 10: 124–8PubMedCrossRefGoogle Scholar
Pascual J, Combarros O, Berciano J. Partial status epileptic us following single low dose of chlorimipramine in a patient on MAO inhibitor treatment. Clin Neuropharmacol 1987; 10: 565–7PubMedCrossRefGoogle Scholar
Lowenstein DH, Massa SM, Rowbotham MC, et al. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 1987; 83: 841–6PubMedCrossRefGoogle Scholar
Washton AM, Tatarsky A. Adverse effects of cocaine abuse. In: Problems of drug dependence: NIDA Research Monograph Series 49. Washington (DC): US Department of Health and Human Services, 1983: 247–54Google Scholar
Alldredge BK, Lowenstein DH, Simon RP. Seizures associated with recreational drug abuse. Neurology 1989; 39: 1037–9PubMedCrossRefGoogle Scholar